Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine

Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease pr...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of pharmacology and toxicology 2024-01, Vol.64 (1), p.455-479
Main Authors: Joshi, Sunil K, Piehowski, Paul, Liu, Tao, Gosline, Sara J.C, McDermott, Jason E, Druker, Brian J, Traer, Elie, Tyner, Jeffrey W, Agarwal, Anupriya, Tognon, Cristina E, Rodland, Karin D
Format: Article
Language:English
Subjects:
drug resistance
Genomics
Humans
Mass Spectrometry
oncoproteomics
Pharmacology & Pharmacy
phosphoproteomics
Precision Medicine
Proteogenomics
Proteomics
single-cell proteomics
Toxicology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of proteogenomics research is that information obtained from proteins and their corresponding pathways provides insight into therapeutic targets that can complement genomic information by providing an additional dimension regarding the underlying mechanisms and pathophysiology of tumors. This review describes the novel insights into tumor biology and drug resistance derived from proteogenomic analysis while highlighting the clinical potential of proteogenomic observations and advances in technique and analysis tools.
ISSN:0362-1642
1545-4304
DOI:10.1146/annurev-pharmtox-022723-113921